Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq

Company Overview - Profusa, Inc. is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [4] - The company aims to provide affordable, long-lasting, injectable biosensors that transmit actionable medical-grade data for personal and medical use [4] Business Combination - Profusa announced the closing of its business combination with NorthView Acquisition Corp. (NVAC), which was approved by NVAC's shareholders on June 9, 2025 [1] - The combined company will operate under the name Profusa, Inc., with common stock expected to begin trading on Nasdaq under the ticker symbol "PFSA" starting July 14, 2025 [1] - A secured convertible promissory note was issued to an institutional investor, raising $9 million to cover transaction costs and support future working capital needs, with a total of up to $20 million available under the convertible note facility [2] Technology and Vision - Profusa's technology platform is designed to continuously monitor and transmit body chemistries to smartphone applications, leveraging advanced data analytics and AI technologies [2] - The company aims to improve health management for chronic diseases such as diabetes, critical limb ischemia (CLI), and peripheral arterial disease (PAD) [2] Leadership and Support - The company is led by a visionary scientific team and an experienced management group, supported by dedicated employees, partners, and investors [2]